Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Total	CRMS	FMC NA	Healthwrox	Common Stock	Common Stock CRMS	Common Stock FMC NA	Additional Paid-in- Capital	Additional Paid-in- Capital CRMS	Additional Paid-in- Capital FMC NA	Accumulated Deficit	Accumulated Deficit FMC NA	Accumulated Other Comprehensive Income	Noncontrolling Interests	Noncontrolling Interests FMC NA	Noncontrolling Interests Healthwrox
Beginning balance (in shares) at Dec. 31, 2021					100,133,953
Beginning balance at Dec. 31, 2021	$ 227,057,024				$ 10,013			$ 283,161,216			$ (63,556,714)		$ (32,501)	$ 7,475,010
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)					195,152
Exercise of stock options	374,344				$ 195			374,149
Stock-based compensation	1,422,937							1,422,937
Equity cost	(19,570)							(19,570)
Noncontrolling interest contribution	2,063,000													2,063,000
Net (loss) income attributable to noncontrolling interests	(1,257,257)													(1,257,257)
Foreign currency translation	(5,863)												(5,863)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	10,629,694										10,629,694
Ending balance (in shares) at Mar. 31, 2022					100,329,105
Ending balance at Mar. 31, 2022	240,264,309				$ 10,208			284,938,732			(52,927,020)		(38,364)	8,280,753
Beginning balance (in shares) at Dec. 31, 2021					100,133,953
Beginning balance at Dec. 31, 2021	227,057,024				$ 10,013			283,161,216			(63,556,714)		(32,501)	7,475,010
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Health liquidation	0
Net (loss) income attributable to noncontrolling interests	(2,924,992)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	26,519,778
Ending balance (in shares) at Sep. 30, 2022					102,824,878
Ending balance at Sep. 30, 2022	270,832,859				$ 10,778			301,522,213			(37,036,937)		(276,213)	6,613,018
Beginning balance (in shares) at Mar. 31, 2022					100,329,105
Beginning balance at Mar. 31, 2022	240,264,309				$ 10,208			284,938,732			(52,927,020)		(38,364)	8,280,753
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock repurchased (in shares)					(70,000)
Common stock repurchased	(497,899)				$ (70)			(497,829)
Exercise of stock options (in shares)					417,927
Exercise of stock options	779,066				$ 418			778,648
Stock-based compensation	1,999,619							1,999,619
UK Ltd. Restricted Stock (in shares)					8,258
UK Ltd. restricted stock	82,305				$ 8			82,297
Net (loss) income attributable to noncontrolling interests	(979,791)													(979,791)
Foreign currency translation	10,434												10,434
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	12,735,653										12,735,653
Ending balance (in shares) at Jun. 30, 2022					100,685,290
Ending balance at Jun. 30, 2022	254,393,696				$ 10,564			287,301,467			(40,191,367)		(27,930)	7,300,962
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)					378,941
Exercise of stock options	728,503				$ 38			728,465
Cashless exercise of options (in shares)					354,276
Cashless exercise of options	(319)				$ 35			(354)
Stock-based compensation	1,015,660							1,015,660
UK Ltd. restricted stock	95,543							95,543
Share warrants conversion (in Shares)					1,406,371
Share warrants conversion	12,381,573				$ 141			12,381,432
Net (loss) income attributable to noncontrolling interests	(687,944)													(687,944)
Foreign currency translation	(248,283)												(248,283)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	3,154,430										3,154,430
Ending balance (in shares) at Sep. 30, 2022					102,824,878
Ending balance at Sep. 30, 2022	$ 270,832,859				$ 10,778			301,522,213			(37,036,937)		(276,213)	6,613,018
Beginning balance (in shares) at Dec. 31, 2022	102,411,162				102,411,162
Beginning balance at Dec. 31, 2022	$ 278,927,391				$ 10,241			301,451,435			(28,972,216)		741,206	5,696,725
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)					96,101
Exercise of stock options	249,715				$ 10			249,705
Stock bases compensation (in shares)					424,911
Stock-based compensation	8,181,591				$ 42			8,181,549
UK Ltd. restricted stock	167,175							167,175
Health liquidation	70,284										70,284
Net (loss) income attributable to noncontrolling interests	(453,120)													(453,120)
Foreign currency translation	243,658												243,658
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	(3,465,670)										(3,465,670)
Ending balance (in shares) at Mar. 31, 2023					102,932,174
Ending balance at Mar. 31, 2023	$ 283,921,024				$ 10,293			310,049,864			(32,367,602)		984,864	5,243,605
Beginning balance (in shares) at Dec. 31, 2022	102,411,162				102,411,162
Beginning balance at Dec. 31, 2022	$ 278,927,391				$ 10,241			301,451,435			(28,972,216)		741,206	5,696,725
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	493,984
Health liquidation	$ (70,284)
Net (loss) income attributable to noncontrolling interests	2,767,084
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	$ (712,016)
Ending balance (in shares) at Sep. 30, 2023	103,874,539				103,874,539
Ending balance at Sep. 30, 2023	$ 291,552,415				$ 10,387			315,745,338			(28,964,781)		808,171	3,953,300
Beginning balance (in shares) at Mar. 31, 2023					102,932,174
Beginning balance at Mar. 31, 2023	283,921,024				$ 10,293			310,049,864			(32,367,602)		984,864	5,243,605
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)					260,410
Exercise of stock options	706,405				$ 26			706,379
Acquisitions (in shares)						117,330	360,145
Acquisitions		$ 1,000,012				$ 12	$ 36		$ 1,000,000	$ (1,432,963)		$ 649,167
Purchase of interests			$ (3,997,716)	$ (1,296,553)											$ (3,213,956)	$ (1,296,553)
Stock bases compensation (in shares)					334,791
Stock-based compensation	3,827,347				$ 33			3,827,314
Shares withheld for taxes (in shares)					(242,758)
Shares withheld for taxes	(2,049,337)				$ (24)			(2,049,313)
Net (loss) income attributable to noncontrolling interests	3,354,886													3,354,886
Foreign currency translation	405,778												405,778
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	(2,011,267)										(2,011,267)
Ending balance (in shares) at Jun. 30, 2023					103,762,092
Ending balance at Jun. 30, 2023	283,860,579				$ 10,376			312,101,281			(33,729,702)		1,390,642	4,087,982
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)					88,837
Exercise of stock options	426,003				$ 8			425,995
Cashless exercise of options (in shares)					6,374
Cashless exercise of options	0				$ 1			(1)
Stock bases compensation (in shares)					30,650
Stock-based compensation	3,335,710				$ 3			3,335,707
Shares withheld for taxes (in shares)					(13,414)
Shares withheld for taxes	(117,645)				$ (1)			(117,644)
Net (loss) income attributable to noncontrolling interests	(134,682)													(134,682)
Foreign currency translation	(582,471)												(582,471)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries	$ 4,764,921										4,764,921
Ending balance (in shares) at Sep. 30, 2023	103,874,539				103,874,539
Ending balance at Sep. 30, 2023	$ 291,552,415				$ 10,387			$ 315,745,338			$ (28,964,781)		$ 808,171	$ 3,953,300